QTI News & Events

QT Imaging reported the characterization of repeatability and reproducibility metrics for quantitative biomarkers generated by its QT Imaging Breast Acoustic CTTM Scanner platform. The study demonstrated high reproducibility across multiple QT Imaging biomarkers. Speed of Sound, a fundamental tissue property measured directly by our scanner, achieved variability of less than 1% both within a scanner and across scanners. Volumetric measurements derived from SoS image volumes demonstrated variability of approximately 5% for Total Breast Volume and 12% for the ratio of fibroglandular volume to total breast volume. The repeatability and reproducibility analysis was conducted at two clinical sites, with five patients enrolled per site and each patient scanned five times per site, characterizing both within-scanner and across-scanner measurement variability.

QT Imaging Holdings announced that its Breast Acoustic CT scanner has received official classification and clearance from the Kingdom of Saudi Arabia, KSA, for use as a medical device in that country. The Saudi Food and Drug Authority, SFDA, approval allows QT Imaging's Breast Acoustic CT scanner to be marketed, sold, and deployed throughout Saudi Arabia, one of the largest healthcare markets in the Middle East. The approval marks a significant milestone in the Company's international expansion strategy and further strengthens its growing commercial presence across the Gulf region.

QT Imaging Holdings announced the pricing of an underwritten public offering of 2,000,000 shares of common stock for gross proceeds of $10M. Ladenburg Thalmann & Co. Inc. is acting as sole book-running manager and Northland Capital Markets is acting as co-manager for the offering. Each share of common stock is being sold to the public at a public offering price of $5.00 per share and each pre-funded warrant is being sold to the public at the public offering price of each share of common stock less the $0.0001 per share nominal exercise price for each pre-funded warrant. Gross proceeds to the Company from this offering are expected to be approximately $10M, before deducting underwriting discounts and commissions and other offering expenses. Each pre-funded warrant will be immediately exercisable, will entitle the holder to purchase one share of common stock, and may be exercised at any time until exercised in full. This offering is expected to close on or about May 18, 2026, subject to the satisfaction of customary closing conditions.